# Highlights of This Issue

## SPECIAL FEATURES

### CCR Translations
- **BAP1tism of a Tumor Suppressor**
  - Scott E. Woodman
  - See article p. 408

### Molecular Pathways
- **Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis**
  - William C. Dougall

### Perspective
- **New Challenges in Endpoints for Drug Development in Advanced Melanoma**
  - Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, and John M. Kirkwood

### Review
- **Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects**
  - Michaela R. Reagan and Irene M. Ghobrial

## HUMAN CANCER BIOLOGY

### Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
- Brooke E. Sylvester, Dezheng Huo, Andrey Khramtsov, Jing Zhang, Rana V. Smalling, Sope Olugbile, Blase N. Polite, and Olufunmilayo I. Olopade

### A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
- Rajsabramaniam Shanmugam, Padmaja Gade, Anique Wilson-Weekes, Hamid Sayar, Attaya Suvannasankha, Chirayu Goswami, Lang Li, Sushil Gupta, Angela A. Cardoso, Tareq Al Baghdadi, Katie J. Sargent, Larry D. Cripe, Dhananjaya V. Kalvakolanu, and H. Scott Boswell

### Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
- Rossitza Lazova, Robert L. Camp, Vincent Khump, Summar F. Siddiqui, Ravi K. Amaravadi, and John M. Pawelek

### Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
- Hiu-Fung Yuen, Ka-Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osama Sharaf Eldin, Ken O’Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, and Mohamed El-Tanani

### Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma
- Yu Sasaki, Hiroaki Takeda, Takeshi Sato, Tomohiko Oriti, Shosichi Nishise, Ko Naquina, Daisuke Iwano, Takao Yaota, Kazuya Yoshizawa, Hideki Saito, Yasuhisa Tanaka, and Sumio Kawata

### Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
- Min-Han Tan, Jessica L. Mester, Joanne Ngeow, Lisa A. Rybicki, Mohammed S. Orloff, and Charis Eng

### Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
- Solange Landreville, Olga A. Agapova, Katie A. Matatall, Zachary T. Kneass, Michael D. Onken, Ryan S. Lee, Anne M. Bowcock, and J. William Harbour

### Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
- Sascha Dietrich, Oliver H. Krämer, Esther Hahn, Claudia Schäfer, Thomas Giese, Michael Hess, Theresa Trettler, Michael Rieger, Jennifer Hullein, Thorsten Zenz, Anthony D. Ho, Peter Dregger, and Thomas Luft
Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma

Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer
Audrey Cras, Beatrice Politis, Nicole Balitrand, Diane Darsin-Bettinger, Pierre Yves Boelle, Bruno Cassinat, Marie-Elisabeth Toubert, and Christine Chomienne

IMAGING, DIAGNOSIS, PROGNOSIS

Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer
Jih-Hsiang Lee, Elisa Giovannetti, Jin-Hyeok Hwang, Iacopo Petri, Quyan Wang, Johannes Voortman, Yonghong Wang, Seth M. Steinberg, Niccola Funel, Paul S. Meltzer, Yisong Wang, and Giuseppe Giaccone

MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

CANCER THERAPY: CLINICAL

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Josman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, and Reinhard Dummer
ABSTRACT

Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.